Variables

Basaln = 54 (%)

6 monthsfollow-upn = 46 (%)
Age (Years) (SD)

42.42 (± 11.11)

43.57 (± 10.10)
Female (Nº) (%)

50 (92.6)

42 (97.3)
Duration of arthritis

≥ 6 weeksto≤ 6 months
> 6 months to≤ 1 year

 

36 (67)
18 (33)

 

--
--
Painful bilateral MTPs compresión

34 (63)

11(24)
ACR 1987 clinical criteria

Morning stiffness
Arthritis of 3 or more areas
Arthritis of hands
Symmetric Arthritis
Rheumatoid Nodules

 

39 (72)
51 (94)
54 (100)
47 (87)
3 (5.5)

 

13 (28)
24 (52)
30 (55.5)
23 (50)
2 (4.3)
DAS 28 (mean) (SD)

4.92 ± (1.03)

3,66 (±1.03)
HAQ (mean) (SD)

1.22 (± 0.78)

0.66 (± 0.28)
ESR (mean) (SD)

37.48 (± 32.98)

29.61 (± 22.88)
FR >1/80 

30 (55.5)

27(58,7)

Anti-CCP>5 mg/dl 

26 (48)

--
CTx-II > 0.3 ng/ml

18 (33.3)

--
ANA

19 (35.2)

4 (8.7)
DMARD

Metotrexate
Anti-malarials
Sulfasalazine
Leflunomide
Anti-TNF
No treatment

 

23 (42.6)
5 (9.3)
2 (3.7)
0
0
24 (44.4)

 

26 (56.5)
8 (17.4)
2 (4.3)
3 (6.5)
1 (2.2)
6 (13.1)
Mortality

 

1* (1.85)
Erosions

15/52

22/38
*Cause of death: Hipoglycemia for sulfonylurea
SD: Standard Deviation; Nº: Number; MTPs: Metatarsophalangeal; ACR: American College of Rheumatology; DAS: Disease Average Score; HAQ: Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; RA-Test: Screening Test for Rheumatoid Factor; Anti-CCP: Antibodies against Citrullinated Peptides; ANA: Antinuclear Antibodies; DMARD: Disease-Modifying Antirheumatic Drugs.
Table 1: Characteristics of the population at baseline and at 6 months follow-up.